Skip to main content
Izotropic Corporation logo

Izotropic Corporation — Investor Relations & Filings

Ticker · IZO ISIN · CA46604F1099 LEI · 529900IZ5PIVM7X6S027 CSE Manufacturing
Open in API
Filings indexed 368 across all filing types
Latest filing 2024-09-30 Regulatory Filings
Country CA Canada
Listing CSE IZO

About Izotropic Corporation

https://izocorp.com/

Izotropic Corporation develops and commercializes diagnostic medical devices, specializing in advanced breast cancer detection technology. Its flagship product is IzoView, a dedicated Breast CT imaging platform. IzoView utilizes high-resolution, true 3D imaging without requiring breast compression, offering superior spatial resolution compared to traditional modalities. The system is purpose-built to improve diagnostic accuracy and patient comfort, particularly targeting the 50% of women with dense breast tissue where conventional screening tools are often inadequate. Izotropic is currently advancing IzoView through pivotal clinical studies toward product launch and commercialization.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate signed by the CEO certifying the review and fair presentation of the Interim Financial Report and Interim MD&A for the period ended July 31, 2024. It is a certification letter rather than the actual interim financial report or MD&A. The document explicitly states it is a certification and does not contain substantive financial data or analysis itself. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the interim report (IR) they reference. The document length is short (3035 characters), consistent with a certification letter rather than a full report. Therefore, the correct classification is Regulatory Filings (RNS).
2024-09-30 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification statement by the CFO of Izotropic Corporation regarding the review and fair presentation of the Interim Financial Report and Interim MD&A for the period ended July 31, 2024. It is a Form 52-109FV2, a certification of interim filings for a venture issuer. The document does not contain actual financial data or substantive financial analysis but is an attestation of the accuracy and completeness of the interim filings. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (3047 characters), and it is clearly a certification letter, not the full interim report.
2024-09-30 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Management’s Discussion and Analysis' (MD&A) for the three months ended July 31, 2024. It contains detailed management commentary on financial condition, results of operations, significant developments including financing activities, outlook, and corporate structure. It references interim financial statements prepared under IAS 34 and IFRS, indicating it is a quarterly or interim report. The length is substantial (15,000 characters), and it contains substantive financial and operational analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2025
2024-09-30 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document contains detailed unaudited condensed interim consolidated financial statements for the three months ended July 31, 2024 and 2023, including statements of financial position, comprehensive loss, changes in shareholders' equity, and cash flows. It also includes notes to the consolidated financial statements, nature of operations, going concern disclosures, and significant accounting policies. The document explicitly states it is an interim financial report prepared under IAS 34 Interim Financial Reporting and IFRS standards. The presence of actual financial data, comprehensive financial statements, and explanatory notes for a period shorter than a full fiscal year confirms this is an Interim / Quarterly Report. The document is 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2025
2024-09-30 English
52-109FV1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings
2024-08-28 English
Annual MD&A - English.pdf
Regulatory Filings
2024-08-28 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.